Allergan 100 Vials - Allergan Refresh Plus Lubricant Eye Drops Single-Use Vials - 100 Ct.

Product Information

difficulty breathing / wheezing, symptoms of allergic reaction (swelling, redness of the eye and rash of the skin), changes in your taste sensation, dizziness, slowing of heart rate, high blood pressure, difficulty sleeping, nightmare, asthma, hair loss, skin discolouration (periocular), tiredness. PRED FORTE suspension is contraindicated in acute untreated purulent ocular infections; in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella; and in mycobacterial infection of the eye and fungal diseases of ocular structures.

OZURDEX ® is a corticosteroid indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).This medicine contains 2.85 mg phosphates in each 3 ml of solution which is equivalent to 0.95 mg/ml. If you suffer from severe damage to the clear layer at the front of the eye (the cornea), phosphates may cause in very rare cases cloudy patches on the cornea due to calcium build-up during treatment.

Potentiation of Vascular Insufficiency: ALPHAGAN ® P may potentiate syndromes associated with vascular insufficiency. ALPHAGAN ® P should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans. Increased IOP with OZURDEX ® peaked at approximately week 8. During the initial treatment period, 1% (3/421) of the patients who received OZURDEX ® required surgical procedures for management of elevated IOP.

Earn points toward rewards

The mechanism of action by which bimatoprost reduces intraocular pressure in humans is by increasing aqueous humour outflow through the trabecular meshwork and enhancing uveoscleral outflow. Reduction of the intraocular pressure starts approximately 4 hours after the first administration and maximum effect is reached within approximately 8 to 12 hours. The duration of effect is maintained for at least 24 hours. It is pertinent to be mindful of the over-the-counter eye drop recalls. Consult the FDA list of affected drops, or ask your eye care practitioner if your drops are safe to use if you’re unsure,” urges Melissa Barnett, OD, director of optometry at UC Davis in California. “An increased risk of infection and potentially vision loss may occur if contaminated drops are used.” It’s been a bad year for eye drops. The U.S. Food and Drug Administration (FDA) has issued yet another eye drop recall—this time focusing on 27 different over-the-counter products over concerns about the potential risk of eye infections that could lead to partial vision loss or blindness.

Ocular adverse reactions reported by greater than or equal to 1% of patients in the two combined 3-year clinical trials following injection of OZURDEX ® for diabetic macular edema include: cataract (68%), conjunctival hemorrhage (23%), visual acuity reduced (9%), conjunctivitis (6%), vitreous floaters (5%), conjunctival edema (5%), dry eye (5%), vitreous detachment (4%), vitreous opacities (3%), retinal aneurysm (3%), foreign body sensation (2%), corneal erosion (2%), keratitis (2%), anterior chamber inflammation (2%), retinal tear (2%), eyelid ptosis (2%). Non-ocular adverse reactions reported by greater than or equal to 5% of patients include: hypertension (13%) and bronchitis (5%). Low blood pressure, swelling or coldness of your hands, feet and extremities, caused by constriction of your blood vessels Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including VUITY. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination.OZURDEX ® (dexamethasone intravitreal implant) is a corticosteroid indicated for the treatment of diabetic macular edema. ocular pruritus in up to 14 % of patients in the first year with the incidence of new reports decreasing to 3 % at 2 years and 0 % at 3 years. Less than 9 % of patients discontinued due to any adverse event in the first year with the incidence of additional patient discontinuations being 3 % at both 2 and 3 years.

To prevent eye injury or contamination, care should be taken to avoid touching the dispensing bottle to the eye or to any other surface. ADVERSE REACTIONS These eye drops, which are intended to be used by people with glaucoma or ocular hypertension, had faulty caps that could lead to unsterile solutions, the FDA noted.Allergic reaction, eye and/or eyelid swelling/puffiness, itchy eyes, red eye, infection of the eye, inflammation of the eye (surface or inside), bleeding of the retina, swelling of central retina (light-sensitive layer of the eye), headache, accidental injury caused by the tip of the dropper touching the eye, increased pressure in the eye, blurred and/or diminished vision. You or your doctor can also report adverse events or quality issues to the FDA’s MedWatch Adverse Event Reporting program.